title: Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder.
abstract: Responses to venlafaxine treatment in major depressive disorder were stratified by COMT genotypes (Val158Met, rs4680) in a randomized, double-blind, placebo-controlled clinical trial. Improvements in depression scores among subjects with Val/Val genotypes were larger than those in Met/Met genotypes, suggesting that venlafaxine may alter noradrenergic flux differentially according to COMT activity.
authors.affiliation: Sunovion Pharmaceuticals Inc, 84 Waterford Dr., Marlborough, MA 01752, USA. seth.hopkins@sunovion.com
authors.forename: Seth C
authors.initials: SC
authors.lastname: Hopkins
authors.forename: David S
authors.initials: DS
authors.lastname: Reasner
authors.forename: Kenneth S
authors.initials: KS
authors.lastname: Koblan
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D003511:Cyclohexanols / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000235:genetics*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008715:Methionine / Q000235:genetics; D008875:Middle Aged; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D011569:Psychiatric Status Rating Scales; D013997:Time Factors; D014633:Valine / Q000235:genetics; D000069470:Venlafaxine Hydrochloride; D055815:Young Adult
chemical_list: D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D000069470:Venlafaxine Hydrochloride; D008715:Methionine; D002394:Catechol O-Methyltransferase; D014633:Valine
keywords: COMT; Major depressive disorder; Venlafaxine